\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Climate, Energy, MobilityThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The Commission has notified that the deadline for call for proposals HORIZON-ER-JU-2024-01, initially foreseen on 7 May 2024, is extended until 5 June 2024 17:00 (Brussels local time).
This applies to all topics under this call:
More information on the reasoning behind this extension of the deadline can be found in the attached document (Reply to question 7 in the 'Questions & Answers to Call for proposals 2024 HORIZON-ER-JU-2024').
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Health Culture and society Security
In the context of simplification, the Commission has introduced the following substantial changes in the Standard Application Form (Version 5.0) for Horizon Europe Research & Innovation Actions (RIA) and Innovation Actions (IA) and Coordination and Support Actions (CSA): Simplified section 2.1 'Project's pathways towards impac... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
